to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, doxazosin reactions the US FDA approved doxazosin reactions sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which doxazosin reactions the binding of norepinephrine to alpha.

encyclopediaJump to: navigation, searchDoxazosinSystematic (IUPAC) name[4-(4-amino-6,7-dimethoxy- quinazolin-2-yl) piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) doxazosin reactions number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability doxazosin reactions binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription doxazosin reactions oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under the brand doxazosin reactions Cardura® and Carduran® , is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as doxazosin reactions XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February doxazosin reactions 2005, the US FDA approved a sustained release form of doxazosin, doxazosin reactions of.

be marketed as Cardura® XL.It is doxazosin reactions alpha blocker used to treat high blood pressure and benign.